BRAF and metastatic colorectal cancer: Yuan et al. recently concluded in a meta-analysis that BRAF mutation is a predictive biomarker and indicates poor prognosis when metastatic colorectal cancer patients are treated with monoclonal antibodies against EGFR (39).